APVO — Aptevo Therapeutics Share News
0.000.00%
Last trade - 00:00Aptevo Therapeutics Inc expected to post a loss of $83.20 a share - Earnings Preview
Brief: Aptevo Therapeutics Files For Offer And Resale Of Up To 8.3 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Aptevo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Aptevo Therapeutics Says In Preclinical Studies APVO711 Demonstrates Dual Anti-Cancer Functionality
Aptevo Therapeutics Inc expected to post a loss of $4.21 a share - Earnings Preview
Aptevo Therapeutics Inc expected to post a loss of $4.21 a share - Earnings Preview
Brief: Aptevo Therapeutics Announces Details On Preclinical Bispecific Antibody APVO442
Brief: Aptevo Therapeutics Announces 1-For 37 Reverse Stock Split As Part Of Nasdaq Compliance Plan
Brief: First Patient Dosed In Ongoing Rainier Trial Achieved 90% Reduction In Leukemic Blasts Within The First 30 Days Of Treatment
Brief: Alligator Bioscience, Aptevo Therapeutics Announce Positive Interim Data From Dose Escalation Phase Of Their Phase 1 Trial
Aptevo Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Aptevo Therapeutics Inc expected to post a loss of $6.55 a share - Earnings Preview
Aptevo Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Aptevo Therapeutics Inc expected to post a loss of $12.84 a share - Earnings Preview
Brief: Alligator Bioscience, Aptevo Therapeutics Announce Positive Interim Data Of Dose Escalation Phase Of ALG.APV-527 Phase 1 Study
Brief: Aptevo Therapeutics Announces H1 2024 Plan For Development Of Lead Candidate APVO436 For Treatment Of Frontline Acute Myeloid Leukemia
Brief: Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split
Brief: Aptevo Therapeutics Says On Sept 13, Co Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Aptevo Therapeutics Inc reports results for the quarter ended in June - Earnings Summary